Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

NCT02860923 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide can help reduce body weight in people who developed obesity after treatment for a craniopharyngioma.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 42 people

Who can join Ages 18–75 · all sexes

Timeline Started 2017-01 · est. completion 2018-09

Where 11 sites · France

What this study is testing ClinicalTrials.gov NCT02860923 ↗

Description as written by the study sponsor.

This hypothalamic obesity is associated with serious metabolic and psychosocial consequences. The purpose of the study is to compare the change of body weight after 6 months treatment with a lifestyle intervention + exenatide compare to the one after the same lifestyle intervention+ placebo in adults patients suffering from a hypothalamic obesity due to treatment of craniopharyngioma.

Treatments tested

Exenatide Drug
Placebo Drug

Main thing measured	Compare body weight change thanks to weighing machine
Sponsor	University Hospital, Bordeaux
Conditions studied	Craniopharyngiomas, Hypothalamic Obesity
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02860923 ↗